Horizon Kinetics Asset Management’s ImmunityBio IBRX Stock Holding History

Horizon Kinetics Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-23,665	Closed	-$291K	–	385
2020 Q2	$291K	Sell	23,665 -30,037	-56%	-$170K	0.01%	295
2020 Q1	$155K	Sell	53,702 -29,178	-35%	-$146K	0.01%	344
2019 Q4	$314K	Sell	82,880 -146,976	-64%	-$250K	0.01%	308
2019 Q3	$280K	Sell	229,856 -51,316	-18%	-$63.7K	0.01%	418
2019 Q2	$287K	Buy	281,172 +21,752	+8%	+$25.1K	0.01%	420
2019 Q1	$410K	Buy	+259,420	New	+$326K	0.01%	277

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Horizon Kinetics Asset Management's IBRX Position: Q3 2020 in Review

Horizon Kinetics Asset Management sold out of ImmunityBio (IBRX) in Q3 2020, closing a stake of 23,665 shares — an estimated $291K sold.

Horizon Kinetics Asset Management first reported a position in IBRX in Q1 2019 and held it in 6 quarters. The position peaked at $410K in Q1 2019. 95 funds tracked by Wall St. Rank hold IBRX as of Q3 2020.

Horizon Kinetics Asset Management reported no remaining ImmunityBio position as of Q3 2020 after selling out during the quarter.
Horizon Kinetics Asset Management sold 23,665 ImmunityBio shares in Q3 2020, an estimated $291K.
Horizon Kinetics Asset Management first reported a position in ImmunityBio in Q1 2019 and held it in 6 quarters.
Horizon Kinetics Asset Management's ImmunityBio position peaked at $410K in Q1 2019.
95 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2020.

Based on Horizon Kinetics Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.